Literature DB >> 15036360

Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain.

C Tassorelli1, F Blandini, R Greco, G Nappi.   

Abstract

Although the involvement of nitric oxide (NO) in mediating pain and neurovascular coupling is well established, the precise mechanisms sustaining these effects are still unclear. Cyclic GMP (cGMP) probably represents the main effector of the biological effects of NO at the vascular and neuronal levels. Nitroglycerin is a NO donor, which easily crosses the blood brain barrier. Several reports have suggested that the study of nitroglycerin effects upon neuronal and cerebrovascular elements is a useful animal model for investigating the pathophysiological mechanisms underlying migraine. In this study, the anatomic distribution of cGMP in the rat brain was evaluated at serial time-points after systemic administration of nitroglycerin or vehicle. The results show an increase in cGMP immunoreactivity in the nucleus trigeminalis caudalis and in the superficial cortical arterioles 2, 3 and 4h after the drug administration. The data obtained sustains the idea that cGMP is an important mediator of nitroglycerin effect in vascular and neuronal structures that are critical elements for the transmission of cephalic pain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15036360     DOI: 10.1016/j.jchemneu.2003.08.006

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  6 in total

1.  Sodium MRI in a rat migraine model and a NEURON simulation study support a role for sodium in migraine.

Authors:  Michael G Harrington; Eduard Y Chekmenev; Victor Schepkin; Alfred N Fonteh; Xianghong Arakaki
Journal:  Cephalalgia       Date:  2011-08-04       Impact factor: 6.292

Review 2.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

3.  Vinpocetine reduces carrageenan-induced inflammatory hyperalgesia in mice by inhibiting oxidative stress, cytokine production and NF-κB activation in the paw and spinal cord.

Authors:  Kenji W Ruiz-Miyazawa; Ana C Zarpelon; Felipe A Pinho-Ribeiro; Gabriela F Pavão-de-Souza; Rubia Casagrande; Waldiceu A Verri
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

4.  Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice.

Authors:  E A Bates; T Nikai; K C Brennan; Y-H Fu; A C Charles; A I Basbaum; L J Ptácek; A H Ahn
Journal:  Cephalalgia       Date:  2010-02       Impact factor: 6.292

5.  Dynamic sodium imaging at ultra-high field reveals progression in a preclinical migraine model.

Authors:  Nastaren Abad; Jens T Rosenberg; David C Hike; Michael G Harrington; Samuel C Grant
Journal:  Pain       Date:  2018-10       Impact factor: 7.926

6.  Botulinum toxin type a therapy in migraine: preclinical and clinical trials.

Authors:  Yu-Feng Shao; Yi Zhang; Peng Zhao; Wen-Jun Yan; Xiang-Pan Kong; Lin-Lan Fan; Yi-Ping Hou
Journal:  Iran Red Crescent Med J       Date:  2013-10-05       Impact factor: 0.611

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.